Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease
Gut microbiota, which act as a determinant of pharmacokinetics, have long been overlooked. In recent years, a growing body of evidence indicates that the gut microbiota influence drug metabolism and efficacy. Conversely, drugs also exert a substantial influence on the function and composition of the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2025.2454937 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583158570156032 |
|---|---|
| author | Yi Zhang Chengjun Mo Penghui Ai Xiaoqin He Qin Xiao Xiaodong Yang |
| author_facet | Yi Zhang Chengjun Mo Penghui Ai Xiaoqin He Qin Xiao Xiaodong Yang |
| author_sort | Yi Zhang |
| collection | DOAJ |
| description | Gut microbiota, which act as a determinant of pharmacokinetics, have long been overlooked. In recent years, a growing body of evidence indicates that the gut microbiota influence drug metabolism and efficacy. Conversely, drugs also exert a substantial influence on the function and composition of the gut microbiota. Pharmacomicrobiomics, an emerging field focusing on the interplay of drugs and gut microbiota, provides a potential foundation for making certain advances in personalized medicine. Understanding the communication between gut microbiota and antiparkinsonian drugs is critical for precise treatment of Parkinson’s disease. Here, we provide a historical overview of the interplay between gut microbiota and antiparkinsonian drugs. Moreover, we discuss potential mechanistic insights into the complex associations between gut microbiota and drug metabolism. In addition, we also draw attention to microbiota-based biomarkers for predicting antiparkinsonian drug efficacy and examine current state-of-the-art knowledge of microbiota-based strategies to optimize drug therapy in Parkinson’s disease. |
| format | Article |
| id | doaj-art-5482d765736e44a6a407c8ac5e54c555 |
| institution | Kabale University |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-5482d765736e44a6a407c8ac5e54c5552025-01-29T03:57:50ZengTaylor & Francis GroupGut Microbes1949-09761949-09842025-12-0117110.1080/19490976.2025.2454937Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s diseaseYi Zhang0Chengjun Mo1Penghui Ai2Xiaoqin He3Qin Xiao4Xiaodong Yang5Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaGut microbiota, which act as a determinant of pharmacokinetics, have long been overlooked. In recent years, a growing body of evidence indicates that the gut microbiota influence drug metabolism and efficacy. Conversely, drugs also exert a substantial influence on the function and composition of the gut microbiota. Pharmacomicrobiomics, an emerging field focusing on the interplay of drugs and gut microbiota, provides a potential foundation for making certain advances in personalized medicine. Understanding the communication between gut microbiota and antiparkinsonian drugs is critical for precise treatment of Parkinson’s disease. Here, we provide a historical overview of the interplay between gut microbiota and antiparkinsonian drugs. Moreover, we discuss potential mechanistic insights into the complex associations between gut microbiota and drug metabolism. In addition, we also draw attention to microbiota-based biomarkers for predicting antiparkinsonian drug efficacy and examine current state-of-the-art knowledge of microbiota-based strategies to optimize drug therapy in Parkinson’s disease.https://www.tandfonline.com/doi/10.1080/19490976.2025.2454937Pharmacomicrobiomicsgut microbiotaParkinson’s diseaseprecision medicine |
| spellingShingle | Yi Zhang Chengjun Mo Penghui Ai Xiaoqin He Qin Xiao Xiaodong Yang Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease Gut Microbes Pharmacomicrobiomics gut microbiota Parkinson’s disease precision medicine |
| title | Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease |
| title_full | Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease |
| title_fullStr | Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease |
| title_full_unstemmed | Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease |
| title_short | Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease |
| title_sort | pharmacomicrobiomics a new field contributing to optimizing drug therapy in parkinson s disease |
| topic | Pharmacomicrobiomics gut microbiota Parkinson’s disease precision medicine |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2025.2454937 |
| work_keys_str_mv | AT yizhang pharmacomicrobiomicsanewfieldcontributingtooptimizingdrugtherapyinparkinsonsdisease AT chengjunmo pharmacomicrobiomicsanewfieldcontributingtooptimizingdrugtherapyinparkinsonsdisease AT penghuiai pharmacomicrobiomicsanewfieldcontributingtooptimizingdrugtherapyinparkinsonsdisease AT xiaoqinhe pharmacomicrobiomicsanewfieldcontributingtooptimizingdrugtherapyinparkinsonsdisease AT qinxiao pharmacomicrobiomicsanewfieldcontributingtooptimizingdrugtherapyinparkinsonsdisease AT xiaodongyang pharmacomicrobiomicsanewfieldcontributingtooptimizingdrugtherapyinparkinsonsdisease |